Clear Street analyst Bill Maughan initiated coverage of Wave Life Sciences (WVE) with a Buy rating and $22 price target The company has proven it can produce “first-in-class and best-in-class” genetic medicines, the analyst tells investors in a research note. The firm says Wave Life has a deep pipeline of attractive drug candidates, lead by WVE-007, which targets obesity.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences Receives Buy Rating Amid Promising AATD Treatment Developments and Strategic Positioning
- Wave Life Sciences Highlights WVE-007 Obesity Treatment
- Invivyd appoints Wave Life Sciences CEO Paul Bolno to board
- B. Riley ‘aggressive’ buyer of Wave Life on ‘material disconnect’
- Wave Life Sciences: Strong Buy Rating Backed by Promising WVE-006 Trial Results and Strategic GSK Partnership